Literature DB >> 22117159

Stereotactic body radiotherapy is an effective treatment in reirradiating spinal metastases: current status and practical considerations for safe practice.

Giuseppina Laura Masucci1, Eugene Yu, Lijun Ma, Eric L Chang, Daniel Letourneau, Simon Lo, Eric Leung, Sam Chao, Derek Hyde, Alessandra Gorgulho, Alex Muacevic, David A Larson, Michael G Fehlings, Arjun Sahgal.   

Abstract

Spinal metastases are a relatively common manifestation in advanced cancer patients. Low-dose conventional radiotherapy has long been the mainstay of treatment under the assumption that patients have a limited life expectancy in the order of 3-6 months. However, with new developments in systemic therapies, patients are surviving longer than expected. As the spinal retreatment rates, secondary to conventional radiation, can approach 20-50%, retreatments are likely to be more frequent. Rather than a second course of even lower-dose conventional radiation, spine stereotactic body radiotherapy (SBRT) has been developed predominantly to overcome the limitations of conventional reirradiation. Spine SBRT permits a second course of high-dose radiation aimed at local tumor control while sparing the spinal cord, and other surrounding normal tissues, of a toxic dose. The focus of this review is to provide an overview of reirradiation spine SBRT, and address key issues surrounding safe and effective practice.

Entities:  

Mesh:

Year:  2011        PMID: 22117159     DOI: 10.1586/era.11.169

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  10 in total

1.  Delayed vertebral body collapse after stereotactic radiosurgery and radiofrequency ablation: Case report with histopathologic-MRI correlation.

Authors:  Adam N Wallace; Ross Vyhmeister; Andy C Hsi; Clifford G Robinson; Randy O Chang; Jack W Jennings
Journal:  Interv Neuroradiol       Date:  2015-10-23       Impact factor: 1.610

2.  Interview: Current state of brain and spine radiosurgery and future applications.

Authors:  Arjun Sahgal
Journal:  CNS Oncol       Date:  2013-01

3.  Radiofrequency ablation and vertebral augmentation for palliation of painful spinal metastases.

Authors:  Adam N Wallace; Taylor J Greenwood; Jack W Jennings
Journal:  J Neurooncol       Date:  2015-05-29       Impact factor: 4.130

Review 4.  Stereotactic body radiotherapy for spinal metastases: a review.

Authors:  Lanlan Guo; Lixin Ke; Ziyi Zeng; Chuanping Yuan; Ziwei Wu; Lei Chen; Lixia Lu
Journal:  Med Oncol       Date:  2022-05-23       Impact factor: 3.064

5.  Separation Surgery in the Treatment of Spinal Metastasis.

Authors:  Rui-Feng Li; Rui-Qi Qiao; Ming-You Xu; Rong-Xing Ma; Yong-Cheng Hu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Stereotactic body radiotherapy treatment of extracranial metastases.

Authors:  Joseph K Salama; John P Kirkpatrick; Fang-Fang Yin
Journal:  Nat Rev Clin Oncol       Date:  2012-09-25       Impact factor: 66.675

Review 7.  Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases.

Authors:  Zain A Husain; Isabelle Thibault; Daniel Letourneau; Lijun Ma; Harald Keller; John Suh; Veronica Chiang; Eric L Chang; Raja K Rampersaud; James Perry; David A Larson; Arjun Sahgal
Journal:  CNS Oncol       Date:  2013-05

8.  Radiographic Local Control of Spinal Metastases with Percutaneous Radiofrequency Ablation and Vertebral Augmentation.

Authors:  A N Wallace; A Tomasian; D Vaswani; R Vyhmeister; R O Chang; J W Jennings
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-03       Impact factor: 3.825

Review 9.  International patterns of practice in radiotherapy for bone metastases: A review of the literature.

Authors:  Rachel McDonald; Edward Chow; Henry Lam; Leigha Rowbottom; Hany Soliman
Journal:  J Bone Oncol       Date:  2014-11-07       Impact factor: 4.072

10.  Intensity-modulated radiotherapy versus proton radiotherapy versus carbon ion radiotherapy for spinal bone metastases: a treatment planning study.

Authors:  Harald Rief; Naved Chaudhri; Eric Tonndorf-Martini; Thomas Bruckner; Stefan Rieken; Tilman Bostel; Robert Förster; Ingmar Schlampp; Jürgen Debus; Florian Sterzing
Journal:  J Appl Clin Med Phys       Date:  2015-11-08       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.